论文部分内容阅读
目的:观察注射用头孢哌酮钠舒巴坦钠(新瑞普欣)治疗下呼吸道感染患者的有效性和安全性。方法:将112例下呼吸道感染患者随机分为治疗组和对照组,治疗组静脉滴注头孢哌酮钠舒巴坦钠2.0g,2次/d,疗程7d。对照组静脉滴注射用头孢曲松钠2.0g,2次/d,疗程7d。比较两组疗效。结果:治疗组和对照组的有效率分别为85%和90.28%,细菌清除率分别为90.41%和91.94%,不良反应发生率为8.33%和7.69%,两组比较无统计学差异(P均>0.05)。结论:新瑞普欣治疗下呼吸道感染疗效高,安全性好。
Objective: To observe the efficacy and safety of cefoperazone sodium and sulbactam sodium for the treatment of patients with lower respiratory tract infection. Methods: One hundred and twelve cases of lower respiratory tract infection were randomly divided into treatment group and control group. The treatment group was given cefoperazone sodium and sulbactam sodium 2.0g twice daily for 7 days. Control group intravenous injection of ceftriaxone sodium 2.0g, 2 times / d, treatment 7d. Compare the two groups curative effect. Results: The effective rates of the treatment group and the control group were 85% and 90.28% respectively, the bacterial clearance rate was 90.41% and 91.94% respectively, and the incidences of adverse reactions were 8.33% and 7.69%. There was no significant difference between the two groups (P > 0.05). Conclusion: The new RAPD treatment of lower respiratory tract infection with high efficacy and good safety.